Xen 45 microstent a reasonable alternative for refractory glaucoma

xen-45-microstent-a-reasonable-alternative-for-refractory-glaucoma.jpg

JAN 18, 2018

Glaucoma


In this multicenter study, investigators evaluated the performance and safety of the Xen 45 ab interno gelatin stent (Allergan) for refractory glaucoma through a 12-month follow-up period.

Study design

The single-arm, open-label clinical trial enrolled 65 patients who experienced a failed filtering or cilioablative procedure (84.6%), or uncontrolled IOP (20–35 mm Hg) on maximum medical treatment (15.4%). They were followed for 12 months after stent implantation.

Outcomes

Approximately 76% of the patients had IOP reductions of at least 20% compared with baseline, on the same or fewer medications. The average drop in IOP was 6.4 mm Hg, and patients were on 2 fewer IOP-lowering medications than they were at baseline. Almost 40% of patients did not require IOP lowering medications following stent placement.

No intraoperative or unexpected postoperative complications were reported. Additional surgical intervention was required in 13.8% of patients due to uncontrolled IOP. About 15% of patients lost an average of 2 lines of vision, which self-resolved in 81% of this subgroup. Other postop complications included transient hypotony (24.6%) and IOP increase of greater than 10 mm Hg (21.5 %).

Limitations

The high percentage of patients who required at least 1 bleb needling (32.3%) may stem from conjunctival dissection prior to sponge application of MMC. The authors were unable to use a subconjunctival MMC injection as it is not FDA approved. There were no comparative arms for the intervention.

Clinical significance

The Xen can be used in refractory glaucoma in the face of failed prior surgery with good results and low complication rates at 12 months. Unlike the iStent or Cypass, it can also be used without cataract surgery.

View Abstract American Journal of Ophthalmology, November 2017

https://www.aao.org/editors-choice/xen-45-microstent-reasonable-alternative-refractor

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more